Lucentis

Novartis, Roche avoid $475M antitrust fine in French appeals court
Novartis, Roche avoid $475M antitrust fine in French appeals court
Fierce Pharma
Novartis
Roche
antitrust
Lucentis
Flag link:
In a win for Regeneron, Novartis' syringe for AMD drug declared 'unpatentable'
In a win for Regeneron, Novartis' syringe for AMD drug declared 'unpatentable'
Endpoints
Regeneron
Novartis
Eylea
drug delivery
patents
Lucentis
Flag link:
Interchangeability without switching studies: FDA explains why a new Lucentis biosimilar may be a game-changer
Interchangeability without switching studies: FDA explains why a new Lucentis biosimilar may be a game-changer
Endpoints
FDA
interchangeability
biosimilars
Lucentis
Roche
Coherus Biosciences
Cimerli
Flag link:
Novartis tips Lucentis to weather the arrival of biosimilar copies in Europe
Novartis tips Lucentis to weather the arrival of biosimilar copies in Europe
Biopharma Reporter
Novartis
Lucentis
biosimilars
patents
Europe
Flag link:
Coherus wins FDA approval for second Lucentis biosimilar, its third drug
Coherus wins FDA approval for second Lucentis biosimilar, its third drug
BioPharma Dive
Coherus Biosciences
biosimilars
Lucentis
Roche
Cimerli
Flag link:
Biogen, Samsung Bioepis launch ranibizumab-nuna in US
Biogen, Samsung Bioepis launch ranibizumab-nuna in US
Ophthalmology Today
Biogen
Samsung Bioepis
ranibizumab
ranibizumab-nuna
biosimilars
Roche
Lucentis
retinal disease
Flag link:
FDA approves first biosimilar to top-selling eye drug Lucentis
FDA approves first biosimilar to top-selling eye drug Lucentis
BioPharma Dive
FDA
biosimilars
Lucentis
age-related macular degeneration
Byooviz
Biogen
Samsung Bioepis
Flag link:
Outlook heads to regulators with eye-friendly Avastin
Outlook heads to regulators with eye-friendly Avastin
EP Vantage
Outlook Therapeutics
Avastin
age-related macular degeneration
FDA
Lucentis
Flag link:
The top 10 drugs losing U.S. exclusivity in 2021
The top 10 drugs losing U.S. exclusivity in 2021
Fierce Pharma
patents
Lucentis
Bystolic
Vascepa
Narcan
Brovana
Sutent
Saphris
Amitza
Feraheme
Flag link:
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar
Pharmaforum
Novartis
Genentech
Lucentis
biosimilars
Samsung Bioepis
Biogen
FDA
Flag link:
Roche, already prepping 2021 launch, charts big expansion plans for Lucentis eye implant
Roche, already prepping 2021 launch, charts big expansion plans for Lucentis eye implant
Fierce Pharma
Roche
macular degeneration
Lucentis
eye implants
wet age-related macular degeneration
Flag link:
Novartis, Roche fined $526M in France for alleged Lucentis marketing missteps
Novartis, Roche fined $526M in France for alleged Lucentis marketing missteps
Fierce Pharma
Novartis
Roche
France
Lucentis
anti-competitive scheme
Flag link:
'No presents anymore': Inside Novartis' scheme to boost Lucentis sales in Greece
'No presents anymore': Inside Novartis' scheme to boost Lucentis sales in Greece
Fierce Pharma
Novartis
Greece
DOJ
Lucentis
kickbacks
physicians
Flag link:
AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis
AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis
Xconomy
AsclepiX Therapeutics
eye disease
Eylea
Lucentis
macular edema
wet age-related macular degeneration
retinal occulsion
AXT107
Flag link:
Biogen signs marketing deal for two ophthalmology biosimilars
Biogen signs marketing deal for two ophthalmology biosimilars
Pharmaforum
Biogen
ophthalmology
biosimilars
Europe
Japan
Samsung Bioepis
SB11
SB15
Lucentis
Eylea
Flag link:
Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?
Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?
Endpoints
Allergan
abicipar
wet age-related macular degeneration
Lucentis
Molecular Partners
Flag link:
Regeneron and Roche Duke it Out in the Diabetic Retinopathy Market
Regeneron and Roche Duke it Out in the Diabetic Retinopathy Market
BioSpace
Regeneron
Eylea
diabetic retinopathy
Roche
Lucentis
Flag link:
Novartis plans to file for new Lucentis indication in ROP
Novartis plans to file for new Lucentis indication in ROP
Pharmaceutical Business Review
Novartis
Lucentis
ROP
retinopathy of prematurity
Flag link:
Roche, Novartis' Italian heads risk trial for alleged market rigging: sources
Roche, Novartis' Italian heads risk trial for alleged market rigging: sources
Yahoo/Reuters
Roche
Novartis
Italy
Avastin
Lucentis
marketing manipulation
Flag link:
Lucentis biosimilar: Formycon eyes 2020 for US launch
Lucentis biosimilar: Formycon eyes 2020 for US launch
BioPharma Reporter
Lucentis
Formycon
Genentech/Roche
FYB201
Flag link:

Pages